

**TREATING GASTROINTESTINAL DYSFUNCTIONS TAKES CENTERSTAGE AT THE ASPEN 2021 NUTRITION SCIENCE & PRACTICE CONFERENCE**

Silver Spring, MD – Live educational sessions and oral abstract presentations on cutting-edge research and evidence-based practices are only part of the virtual ASPEN 2021 Nutrition Science & Practice Conference on March 20-23. ASPEN21 also offers opportunities to exchange ideas and experiences with experts and colleagues from around the globe.

Presentations of particular interest to GI clinicians are available each day of the conference. Highlights include:

- March 20: Post Graduate Pre-Conference Course: Select GI Disease States and Nutritional Implications
- March 21: Nutritional Management of Treatment Induced Gastrointestinal Complications
- March 22: Advances in Preventing Parenteral Nutrition Associated Side Effects
- March 23: Nutritional Metabolomics: Back to the Future of Nutrition and Metabolic Support

ASPEN21 provides opportunities to join an array of focused breakout sessions, specialty forums, exhibits, poster presentations, and corporate symposia.

For program details, continuing education information, and to register for the full conference, individual days, and pre-conference courses, visit:

**[nutritioncare.org/conference21](https://nutritioncare.org/conference21)**

**About American Society for Parenteral and Enteral Nutrition**

ASPEN, the American Society for Parenteral and Enteral Nutrition, is dedicated to improving patient care by advancing the science and practice of nutrition support therapy and metabolism. Founded in 1976, ASPEN is an interdisciplinary organization whose members are involved in the provision of clinical nutrition therapies, including parenteral and enteral nutrition.

For more information about ASPEN, please visit: **[nutritioncare.org](https://nutritioncare.org)**

**[practicalgastro.com](https://practicalgastro.com)**

**ECHOSENS PARTNERS WITH GASTROLOGIX TO PROVIDE INDEPENDENT GI PRACTICES WITH FIBROSCAN FOR NON-INVASIVE, COST-EFFECTIVE LIVER HEALTH EXAMINATIONS**



Waltham, Massachusetts – January 26, 2021 – Echosens, a high-technology company offering the FibroScan family of products, announces its partnership with Gastrologix to provide independent GI practices in its group purchasing organization (GPO) with the enhanced services of FibroScan, a non-invasive device that helps to assess liver health.

FibroScan is used by GI physicians to identify and address nonalcoholic fatty liver disease (NAFLD) and its more severe form nonalcoholic steatohepatitis (NASH), which have been recognized as leading causes of liver disease and key contributors to increased cardiovascular disease (CVD) mortality among people living with Type 2 diabetes.

“Given the alarming rise in liver disease, FibroScan will help independent GI practices to improve patient outcomes and reduce the costs associated with managing chronic liver conditions,” says Stephen Somers, principal of Gastrologix. “This innovative technology should be an integral part of a chronic care management program in any independent GI practice. In addition to providing a valuable service to patients, FibroScan can help sustain the practice financially as well.”

NAFLD has become the most common chronic liver disease in the world and affects between 25% to 30% of adults in the United States. About 20% of patients with NAFLD will progress to NASH, with about 25% of these individuals likely to

*(continued on page 42)*

*(continued from page 40)*

develop liver fibrosis. Because NAFLD and NASH are tightly intertwined with obesity, diabetes and lifestyle, patients benefit from coordinated engagement to support changes in lifestyle that affect liver disease progression and result in better outcomes.

Jon Gingrich, CEO, Echosens North America, says “We’re excited to be able to bring FibroScan to the Gastrologix customer base. GI practices are at the forefront of the fight against the liver disease epidemic and can use our technology as part of their efforts to improve outcomes, save lives and, in these challenging times, initiate income repair for their practices.”

**About Echosens**

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.

For more information, please visit:  
**echosens.us**

**About Gastrologix**

Gastrologix is the only Group Purchasing Organization (GPO) in the U.S. working strictly on behalf of independent gastroenterologists. Gastrologix works with independent GI practices in a business development capacity to lower costs, operate more efficiently and expand services, so that GI physicians can remain independent and continue to provide a valuable alternative to the more expensive care provided in hospitals.



**SEBELA PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF SUTAB® TABLETS, AN ALTERNATIVE TO LIQUID COLONOSCOPY PREPARATION**  
*SUTAB® Tablets with Active Sulfate Ingredients is the First Tablet Colonoscopy Preparation to Receive FDA Approval in Over 10 Years*



ROSWELL, GA, Jan., 2021—Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States.

SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alternative to liquid colonoscopy preparations, which traditionally require consuming large volumes of poor-tasting solution and can often be a barrier to patients’ willingness to undergo colonoscopy screening for colorectal cancer.<sup>1</sup>

The American Cancer Society and the U.S. Preventive Services Task Force recommend adults undergo screening for colorectal cancer beginning at age 45.<sup>2</sup> Colonoscopy is the gold standard detection method for colorectal cancer, a leading cause of cancer-related deaths that can be more effectively treated if caught early through screening.<sup>3</sup> Within the last decade, the rate of colonoscopy procedures has increased significantly with approximately 18 million people now screened annually for colorectal cancer.

*(continued on page 44)*

(continued from page 42)

“Alternative colonoscopy preparations, like SUTAB, can play an important role in encouraging more patients to get screened for colorectal cancer,” said Alan Cooke, President and CEO of Sebelo Pharmaceuticals. “With the introduction of SUTAB tablets, we hope to take yet another important step toward removing some of the burden often associated with the preparation process – allowing more patients to feel confident in their choice to undergo a colonoscopy.”

The FDA approved SUTAB on November 10, 2020. The approval was based on positive Phase 3 clinical trials, which evaluated the safety and efficacy of SUTAB compared to FDA-approved preparations in 941 patients, including a traditional polyethylene glycol and ascorbate preparation (PEG-EA) for bowel cleansing prior to a colonoscopy.<sup>4</sup>

A high rate of cleaning success was seen with SUTAB (92.4%), which demonstrated non-inferiority to PEG-EA (89.3%).<sup>4</sup> Likewise, the percentage of patients rating their overall experience with SUTAB as “excellent” or “good” was higher than those rating PEG-EA (71.6% vs. 59.8%, respectively).<sup>4</sup> For a future colonoscopy, 78% of patients said they would request SUTAB again.<sup>4</sup>

SUTAB is now available by prescription in the U.S. and is competitively priced with other branded colonoscopy preparations. Patients can pay as little as \$40 with a Braintree copay card.

To learn more, visit:  
**SUTAB.com**

SUTAB was developed by Braintree, the makers of SUPREP® Bowel Prep Kit (sodium sulfate, potassium sulfate and magnesium sulfate) Oral Solution for adults—the market leader in branded colonoscopy preparations.<sup>5</sup> Braintree, a leader in gastroenterology, is part of Sebelo Pharmaceuticals.

**IMPORTANT SAFETY INFORMATION**

SUTAB® (sodium sulfate, magnesium sulfate, potassium chloride) tablets for oral use is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

**DOSAGE AND ADMINISTRATION:** A low residue breakfast may be consumed. After breakfast, only clear liquids may be consumed

until after the colonoscopy. Administration of two doses of SUTAB (24 tablets) are required for a complete preparation for colonoscopy. Twelve (12) tablets are equivalent to one dose. Water must be consumed with each dose of SUTAB and additional water must be consumed after each dose. Complete all SUTAB tablets and required water at least 2 hours before colonoscopy.

**CONTRAINDICATIONS:** Use is contraindicated in the following conditions: gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention.

**WARNINGS AND PRECAUTIONS:** Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing; Suspected GI obstruction or perforation: Rule out the diagnosis before administration.

**ADVERSE REACTIONS:** Most common gastrointestinal adverse reactions are: nausea, abdominal distension, vomiting and upper abdominal pain.

**DRUG INTERACTIONS:** Drugs that increase risk of fluid and electrolyte imbalance.<sup>6</sup>

**About SUTAB®**

SUTAB® (sodium sulfate, magnesium sulfate, potassium chloride) tablets for oral use is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. Cleaning the colon helps a healthcare provider see the inside of a colon more clearly during a colonoscopy. Safety and effectiveness of SUTAB® in pediatric patients have not been established.<sup>6</sup>

**About Sebelo Pharmaceuticals®**

Sebelo Pharmaceuticals is a US-focused, growth-oriented specialty pharmaceutical company developing and commercializing gastroenterology, women’s health, and dermatology prescription

(continued on page 46)

(continued from page 44)

products. Braintree, a part of Sebelo Pharmaceuticals, is a pioneer in gastroenterology therapy for bowel cleansing prior to colonoscopy screening for colorectal cancer having developed multiple innovative prescription colonoscopy preparation and constipation products including SUTAB<sup>®</sup>, SUPREP<sup>®</sup> Bowel Prep Kit, GoLYTELY<sup>®</sup> and NuLYTELY<sup>®</sup>. Our gastroenterology product line also includes Motofen<sup>®</sup>, Analpram HC<sup>®</sup> and recently approved Pizensy<sup>™</sup> (indicated for chronic idiopathic constipation in adults). Sebelo Pharmaceuticals has multiple further advances in colonoscopy preparation therapy in clinical development. Sebelo Pharmaceuticals also has two next generation intra-uterine devices (IUDs) for contraception in development that hold the promise of a better patient experience in addition to excellent efficacy. Sebelo Pharmaceuticals has offices in Roswell, GA; Braintree, MA; and Dublin, Ireland, has annual net sales of \$200-250 million and has grown to over 300 employees through strategic acquisitions and organic growth.

Please visit [sebelopharma.com](http://sebelopharma.com) for more information or call **800-874-6756**

### **Forward Looking Statements**

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sebelo Pharmaceuticals under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," "forecast," "estimated," "expected," and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the development, launch, introduction and commercial potential of SUTAB<sup>®</sup>; growth and opportunity, including peak sales and the potential demand for SUTAB<sup>®</sup>, as well as its potential impact on applicable markets; market size; substantial competition; our ability to continue as a growing concern; our need for additional financing; uncertainties of patent protection and litigation;

uncertainties of government or third-party payer reimbursement; dependence upon third parties; our financial performance and results, including the risk that we are unable to manage our operating expenses or cash use for operations, or are unable to commercialize our products, within the guided ranges or otherwise as expected; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Sebelo Pharmaceuticals does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances except as required by law.

### **References**

1. Parra-Blanco A, Ruiz A, Alvarez-Lobos M, et al. Achieving the best bowel preparation for colonoscopy. *World J Gastroenterol*. Published online December 21, 2014. doi: 10.3748/wjg.v20.i47.17709
2. U.S. Preventative Services Task Force. Colorectal Cancer: Screening. <https://www.uspreventiveservices-taskforce.org/uspstf/draft-recommendation/colorectal-cancer-screening3>. October 27, 2020. Accessed December 21, 2020.
3. Doubeni CA, Corley DA, Quinn VP, et al. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. *Gut*. 2018;67(2):291-298.
4. Di Palma JA, Bhandari R, Cleveland M, et al. A safety and efficacy comparison of a new sulfate-based tablet bowel preparation versus a PEG and ascorbate comparator in adult subjects undergoing colonoscopy. *Am J Gastroenterol*. Published online November 6, 2020. doi: 10.14309/ajg.0000000000001020
5. IQVIA. National Prescription Audit Report. December 2020.
6. SUTAB<sup>®</sup> [package insert]. Braintree Laboratories, Inc., Braintree, MA: 2020.